Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 6, 2013, Pages 348-359

  Zhang, Tao ^a,b   Li, Yanyan ^a,c   Zou, Peng ^a   Yu, Jing Yu ^a   McEachern, Donna ^a   Wang, Shaomeng ^a   Sun, Duxin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c MONTCLAIR STATE UNIVERSITY   (United States)

Author keywords

human breast cancer; mouse xenograft model; multiple inhibitor of apoptosis proteins (IAPs); pharmacodynamic modeling; SM 406 AT 406

Indexed keywords

ANTINEOPLASTIC AGENT; AT 406; INHIBITOR OF APOPTOSIS PROTEIN 1; ONCOPROTEIN; PROCASPASE 8; PROTEIN INHIBITOR; SM 406; SM 408; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HEART; HUMAN; HUMAN CELL; INTESTINE; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PROTEIN AGGREGATION; SINGLE DRUG DOSE; SPLEEN; TUMOR GROWTH; TUMOR XENOGRAFT;

HUMAN BREAST CANCER; MOUSE XENOGRAFT MODEL; MULTIPLE INHIBITOR OF APOPTOSIS PROTEINS (IAPS); PHARMACODYNAMIC MODELING; SM-406/AT-406;

ANIMALS; ANTINEOPLASTIC AGENTS; AZOCINES; BENZHYDRYL COMPOUNDS; BREAST NEOPLASMS; CASPASE 8; CELL LINE, TUMOR; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, SCID; MODELS, BIOLOGICAL; POLY(ADP-RIBOSE) POLYMERASES; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883740826     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1850     Document Type: Article

References (32)

1. Nicholson DW,. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407: 810-816.
2. Ponder BA,. Cancer genetics. Nature 2001; 411: 336-341.
3. Lowe SW, Lin AW,. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
4. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Salvesen GS, Duckett CS,. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-410.
6. Deveraux QL, Reed JC,. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
7. Holcik M, Gibson H, Korneluk RG,. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001; 6: 253-261.
8. Du C, Fang M, Li Y, Li L, Wang X,. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
9. Verhagen AM, Ekert PG, Pakusch M, et al,. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
10. Srinivasula SM, Hegde R, Saleh A, et al,. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112-116.
11. Shiozaki EN, Chai J, Rigotti DJ, et al,. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003; 11: 519-527.
12. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y,. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000; 406: 855-862.
13. Liu Z, Sun C, Olejniczak ET, et al,. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408: 1004-1008.
14. Cai Q, Sun H, Peng Y, et al,. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011; 54: 2714-2726.
15. Nestorov I,. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007; 3: 235-249.
16. Derendorf H, Lesko LJ, Chaikin P, et al,. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 2000; 40: 1399-1418.
17. Zhang T, Hamza A, Cao X, et al,. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008; 7: 162-170.
18. Laufer R, Paz OG, Di Marco A, et al,. Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors. Drug Metab Dispos 2009; 37: 873-883.
19. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP,. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407-484.
20. Baxter LT, Zhu H, Mackensen DG, Jain RK,. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994; 54: 1517-1528.
21. Wang P, Ba ZF, Burkhardt J, Chaudry IH,. Trauma-hemorrhage and resuscitation in the mouse: effects on cardiac output and organ blood flow. Am J Physiol 1993; 264: H1166-H1173.
22. D'Argenio DZ, Schumitzky A, Wang X,. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource: Los Angeles, 2009.
23. Dai Y, Liu M, Tang W, et al,. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 2009; 9: 392.
24. Roth W, Reed JC,. Apoptosis and cancer: when BAX is TRAILing away. Nat Med 2002; 8: 216-218.
25. Cao X,. Simultaneously targeting hypoxic cancer cells by hsp90 inhibitor and glycolysis inhibitor in pancreatic cancer therapy. In College of Pharmacy. The Ohio State University: Columbus, 2007; 239.
26. Bissery MC, Vrignaud P, Lavelle F, Chabot GG,. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996; 7: 437-460.
27. Norton L, Simon R,. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 1977; 58: 1735-1741.
28. Simeoni M, Magni P, Cammia C, et al,. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004; 64: 1094-1101.
29. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, Melendez-Zajgla J,. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 2008; 27: 48.
30. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ,. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 2003; 30: 185-219.
31. Yamazaki S, Nguyen L, Vekich S, et al,. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther 2011; 338: 964-973.
32. Salphati L, Wong H, Belvin M, et al,. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010; 38: 1436-1442.